Funder: National Institutes of Health

Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision) | October 5, 2026 (New) | November 5, 2026 (Renewal/Resubmission/Revision) | February 5, 2027 (New) | March 5, 2027 (Renewal/Resubmission/Revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/Resubmission/Revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/Resubmission/Revision)

Funding Amounts: Up to $1,500,000 direct costs/year; up to 5 years (Early Stage) or 4 years (Late Stage) per project.

Summary: Supports pre-clinical and Phase I clinical development of novel small-molecule and biologic drug candidates to prevent, slow, or treat Alzheimer's disease, excluding basic research and non-pharmacological interventions.

Key Information: Applications focused on anti-amyloid, anti-tau, repurposed drugs, combination therapies, or stand-alone clinical trials are not eligible.